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Abstract
Background: African American men have the highest prostate cancer morbidity and mortality rates than any
other racial or ethnic group in the US. Although the overall incidence of and mortality from prostate cancer has
been declining in White men since 1991, the decline in African American men lags behind White men. Of
particular concern is the growing literature on the disproportionate burden of prostate cancer among other Black
men of West African ancestry in the Caribbean Islands, United Kingdom and West Africa. This higher incidence
of prostate cancer observed in populations of African descent may be attributed to the fact that these populations
share ancestral genetic factors. To better understand the burden of prostate cancer among men of West African
Ancestry, we conducted a review of the literature on prostate cancer incidence, prevalence, and mortality in the
countries connected by the Transatlantic Slave Trade.
Results: Several published studies indicate high prostate cancer burden in Nigeria and Ghana. There was no
published literature for the countries Benin, Gambia and Senegal that met our review criteria. Prostate cancer
morbidity and/or mortality data from the Caribbean Islands and the United Kingdom also provided comparable
or worse prostate cancer burden to that of US Blacks.
Conclusion: The growing literature on the disproportionate burden of prostate cancer among other Black men
of West African ancestry follows the path of the Transatlantic Slave Trade. To better understand and address the
global prostate cancer disparities seen in Black men of West African ancestry, future studies should explore the
genetic and environmental risk factors for prostate cancer among this group.
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Introduction
In the United States (US), an estimated 30,870 cases of
prostate cancer are expected to occur among African
American men in 2007, accounting for 37% of all cancers
diagnosed in African American men [1]. Between 2000
and 2003, the average annual prostate cancer rate was
60% higher in African American men compared to White
men [1]. In addition, African American men have the
highest mortality rate compared to any other racial or eth-
nic group in the US, and 2.4 times higher than in White
men. Although prostate cancer incidence and mortality
rates have been declining in both African American and
White men since 1991, possibly due to improved diagnos-
tic techniques, better screening and improved surgical and
radiologic treatments, the rates remain comparably higher
among African American men. Why does this disparity con-
tinue to exist among African American men in spite of the sig-
nificant research to eliminate this disparity?
The population-based studies on prostate cancer disparity
have traditionally studied African American men only or
compared African American men to other racial groups
within the US. Although these studies have provided vital
insights necessary to understanding the primary differ-
ences among the ethnic groups in the US, we are left with
more questions than answers. With the problem of pros-
tate cancer disparity persisting, it is crucial that we begin
to use new paradigms to examine the problem of prostate
cancer disparity from new perspectives. The prospect for a
new paradigm/new perspectives emerge with the growing
literature on the disproportionate burden of prostate can-
cer among other Black men (in other parts of the world,
other than the US) who are related to African American
men through the Transatlantic Slave Trade (TAS) [2-7],
especially Black men of West African ancestry. Based on
the World Health Organization (WHO)'s worldwide can-
cer data, West African men have much lower prostate can-
cer incidence and mortality compared to African
American men. For example, compared to Nigerian men,
African-American men are >10 times likely to develop
prostate cancer and 3.5 times likely to die from the disease
[8]. On the other hand, Silverberg and Lubera [9] reported
high rates of prostate cancer mortality in Martinique,
Trinidad & Tobago; while Glover et al. [10]reported high
rates of prostate cancer incidence in the predominantly
Afro-Caribbean population of Jamaica. Thus the variabil-
ity in risk and mortality across these populations of West
African descent suggests a potential and important influ-
ence of environmental/lifestyle factors acting on prostate
cancer risk in these already susceptible populations. Can
this evolving international data hold the key to our better
understanding of the etiology of unequal burden of this disease
in African American men?
The Transatlantic Slave Trade (TAS) Relations
Based on the TAS, about 15 million people were trans-
ported as slaves from Africa, not counting those who died
en-route to the Americas, Caribbean and Europe [7]. The
TAS comprised the following three journeys: (1) Outward
passage from Europe to Africa carrying manufactured
goods; (2) Middle passage from Africa to the Americas/
Caribbean carrying African captives and other commodi-
ties; and (3) Homeward passage carrying sugar, tobacco,
rum, rice, cotton and other goods back to Europe. These
slave routes included diverse countries. The European
countries involved in the TAS were Portugal, France, Neth-
erlands, Spain, Denmark, Norway and United Kingdom.
Slaves were primarily imported from the African countries
– Benin, Nigeria, Ghana, Gambia, Senegal, Mozambique,
and Angola. The middle passage took the slaves from
Africa to the American and Caribbean countries – Barba-
dos, Cuba, Haiti, Dominican Republic, Netherlands Anti-
lles, Trinidad and Tobago, Jamaica, Brazil, and the US.
Most of the slaves ended up in South America or the Car-
ibbean with about 500,000 transported to North America.
Unfortunately, most of the slaves in the Caribbean, Cen-
tral America and South America died while the slave pop-
ulation in North America had higher life expectancy [7].
Objective
In this manuscript, we explored the burden of prostate
cancer among the TAS population targeting Black men of
West African Ancestry to answer the question:Does the
prostate cancer disparities seen in Black men around the world
follow the path of the TAS?
Methods
To achieve the objective for this study, we conducted a lit-
erature review, summarizing the body of evidence on
prostate cancer morbidity and mortality in countries with
high population of Black men of West African ancestry,
excluding the US. Our goal was not to provide a meta-
analysis evaluation nor conduct a comprehensive review/
critique of these studies. Our aim was to merely examine
the available proof in an effort to better understand the
burden of prostate cancer among Black men of West Afri-
can ancestry. The study countries for our review were West
African TAS populations (Benin, Nigeria, Ghana, Gambia,
and Senegal), the United Kingdom and Caribbean Islands
(Barbados, Cuba, Haiti, Dominican Republic, Nether-
lands Antilles, Trinidad and Tobago, Jamaica, and Brazil).
A systematic search of the computerized database,
MEDLINE, was conducted for each country from the orig-
inating date of MEDLINE to July 2008 using the following
keywords: Black men, prostate cancer, prostate cancer risk,
prostate cancer incidence; prostate cancer morbidity; and
name of TAS country. The inclusion criteria were:
￿ Original studies and review articles;Infectious Agents and Cancer 2009, 4(Suppl 1):S2 http://www.infectagentscancer.com/content/4/S1/S2
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￿ Publication in English;
￿ Relevance to prostate cancer risk, incidence, prevalence
or mortality; and
￿ Sufficient quality and quantity of evidence based on
study design and validity, for example, well designed ran-
domized/non-randomized study with good evidence to
support study conclusion.
Studies employing the World Health Organization
(WHO) GLOBOCAN program of the International
Agency for Research in Cancer (IARC) [11] were excluded
from the review because the data from developing coun-
tries are unreliable. As noted in the GLOBOCAN 2002
report [11], several developing countries do not have
available data for cancer incidence and mortality. Thus,
data from neighboring countries in the same regions were
used to estimate developing countries. For example, the
incidence data for each West African country were esti-
mated from the proportions of available data from the
respective country as well as un-weighted averages of the
observed rates (by sex and age-group) in registries from
other West African countries. The cancer mortality for
these countries was calculated as the product of incidence
and the probability of dying from the disease. The pooled
estimates of survival for the West African regions were
applied to countries in these regions. Given the lack of
reliable and valid cancer incidence and mortality data for
most of the developing countries, the prostate cancer rates
reported in the Globocan 2002 report [11] for these coun-
tries are underestimated.
The steps for the literature review were in the following
order: Step 1 Search for relevant articles using specified
keywords on MEDLINE; Step 2 Screening of Titles to elim-
inate irrelevant articles; Step 3 Screening of abstracts of all
articles identified in Step 2 for relevance; and Step 4
Review of papers identified in Step 3 based on inclusion
criteria by study investigators. Only the studies with study
design ranked Excellent, Good  or Satisfactory  by authors
were included in the review. Subsequently, the studies
were grouped together and summarized according to TAS
country. It is important to note that some of the studies
included more than one (1) TAS country.
Results
Results are presented for each region below.
Tracing the root of prostate cancer disparities to West 
Africa
The lack of population-based cancer registries in develop-
ing countries, especially African countries, leaves only
hospital-based prostate cancer morbidity and mortality
data. Thus, most of the articles identified in our review
presented only hospital-based data. There was no pub-
lished study on prostate cancer morbidity and mortality
in Benin, Gambia, and Senegal. Although there was no pub-
lished study reporting prostate cancer morbidity and mor-
tality in Senegal, Gueye et al. [12] found the clinical
characteristics of prostate cancer among the Senegalese
(median PSA of 37.0 ng/mL) to be different from Ameri-
can Blacks (median PSA of 6.3 ng/mL) and Whites
(median PSA of 6.1 ng/mL); p < 0.001. Senegalese men
had worse median (and mean) PSA level and worse tumor
stage. As noted by the authors, these differences can pos-
sibly be explained by the considerable differences in early
detection between US men and Senegalese men.
Reports on prostate cancer patterns in Ghanaian men were
found in only two published studies. The first study was a
review of the genitourinary cancers seen at the Accra
Korle-Bu Teaching Hospital, Klufio [13]. The authors
found prostate cancer to comprise about 64% (349 cases)
of all genitourinary cancers from 1980 to 1990. In a more
recent study, Wiredu and Armah [14] conducted a 10-year
review (1991–2000) of all cancer mortality patterns at the
same institution based on autopsy and death certification
data, and found prostate cancer to be the second leading
cause of cancer deaths (286 cases). None of the studies
presented the actual incidence, prevalence or mortality
from prostate cancer.
Contrary to the WHO IARC global ranking, several pub-
lished studies indicate higher incidence of prostate cancer
in Nigerian men. A total of 17 original papers, which met
our review criteria, were found to document prostate can-
cer patterns in Nigeria. Odedina, Ogunbiyi and Ukoli pre-
viously reviewed all the 17 articles in 2006 [8]. The first
published paper reviewed by Odedina, Ogunbiyi and
Ukoli [8] was as early as 1981 and the latest study in 2005.
The studies were conducted in different regions of Nigeria,
including the North, Southeast, West, and in rural South.
The authors concluded that the body of evidence from the
17 studies indicates high prostate cancer risk among Nige-
rian men and a prostate cancer burden similar to that of
Black men in the US. Table 1 provides a summary of the
prostate cancer incidence and prevalence rates reported in
the review article.
Tracing the root of prostate cancer disparities to 
Caribbean Islands
There were no published articles that met our review crite-
ria for the countries Barbados, Cuban, Dominican Republic,
Haiti, and Netherlands Antilles. Three published studies
met the criteria for prostate cancer patterns in Brazil. The
earliest study, in 1991, reviewed the Cancer Registry data
of São Paulo between 1969 and1974 [15] and found
Mulatto and Black men to be disproportionately affected
by prostate cancer compared to White men. The authorsInfectious Agents and Cancer 2009, 4(Suppl 1):S2 http://www.infectagentscancer.com/content/4/S1/S2
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concluded that the prostate cancer disparities seen among
Mulattos and Blacks in Brazil were similar to the experi-
ences of Blacks in the US. In another study of Blacks,
Mulattos and Whites, Barros et al. [16] explored the prev-
alence of prostate cancer from 1999 to 2001 at the Federal
University of Bahia's hospital. Based on a sample of 162
patients who had prostate biopsy, the authors found no
statistically significant differences among the three ethnic
groups on mean PSA level (22.0 ng/dl for White, 18.1 ng/
dl for Mulatto, and 19.3 ng/dl for Black; p value of 0.65)
and prostate adenocarcinoma prevalence (53.3% for
White, 53.3% for Mulatto, and 64.9% for Black; p value of
Table 1: Comparison data on incidence and prevalence of prostate cancer in Black Men of West African ancestry
Country Author Incidence rate per 100,00 Prevalence rate Source of data
West Africa
Nigeria Osegbe, 1998 [32] 127.0 - Hospital-based data; for men 45 years or 
older
Nigeria Ekwere & Egbe, 2002 [37] 61.3 - Hospital-based data; for men 35 years or 
older
Nigeria Eke & Sapira, 2002 [33] 114.0 - Hospital-based data; for men 45 years or 
older
Nigeria Ukoli et al., 2003 [26]- 15.7% Rural Nigerian population-based; PSA = 4 
ng/mL for men 50 years & older
Caribbean
Jamaica Glover et al., 1998 [10] 304.0 - Large population-based study; age-adjusted 
rate
Jamaica Hanchard et al., 2001 [19] 56.4 - Cancer registry data; age-adjusted rate
Tobago Bunker et al., 2002 [22]- 10.0% Large population-based study; biopsy 
confirmed for men 40–79 years
Tobago Bunker et al., 2004 [21]- 10.7% Large population-based study; biopsy 
confirmed for men 40–79 years
Brazil Barros et al., 2003 [16]- 19.7% Hospital-based data; for men 40–79 years
Europe
United Kingdom Chinegwundoh et al., 2006 [24] 647.0 - Population-based audit for African-
Caribbean (all blacks); age-adjusted rate for 
men 50 years or older over 2 years
United Kingdom Ben-Shlomo et al., 2007 [25] 165.5 - Population-based audit for African-
Caribbean (all Blacks); age-adjusted rate for 
men 50 years or older over 5 years
United Kingdom Ben-Shlomo et al., 2007 [25] 173.1 - Population-based audit for Black 
Caribbean; age-adjusted rate for men 40 
years or older over 5 years
United Kingdom Ben-Shlomo et al., 2007 [25] 139.3 - Population-based audit for Black African 
(all blacks); age-adjusted rate for men 40 
years or older over 5 years
United States
US Black Men ACS, 2008 [1] 258.30 SEER 2000 – 2003 dataInfectious Agents and Cancer 2009, 4(Suppl 1):S2 http://www.infectagentscancer.com/content/4/S1/S2
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0.36). The final study in Brazil targeted a population with
a high number of Bantu African ancestors in São Paulo.
Screening 473 volunteers between the age of 40 and 79,
Paschoalin et al. [17] found the prevalence of prostate
cancer to be greater among Blacks and Mulattos compared
to Whites. The proportion of biopsy-confirmed prostate
cancer among 121 patients were 8.5% Black men, 6.7%
for Mulatto men, and 0.6% for White men (p = 0.006).
The classic study by Glover et al. [10] in 1998 provided a
significant update on prostate cancer in Jamaica. Prior to
this study, African American men were cited as having the
highest rate for prostate cancer in the world. Glover et al.
[10] conducted a 5-year retrospective review of over 1,000
prostate cancer cases between 1989 and 1994 in Kingston,
Jamaica. The authors reported a mean-age adjusted inci-
dence rate of 304 per 100,000 based on 1,121 prostate
cancer cases retrieved from the Jamaican Cancer Registry,
government pathology laboratory, hospital and clinic
records, and physician office records. The authors con-
cluded that the prostate cancer incidence in Kingston was
significantly higher than that of the US Blacks. Glover et
al. [10] confirmed the results from an earlier study by
Brooks and Wolf [18], who found prostate cancer to be
the most prevalent cancer among Jamaican men in King-
ston and St. Andrew based on a review of all cancer cases
from 1958 to 1987. More recently, Hanchard et al. [19] in
2001 reported prostate cancer as the leading site for inci-
dence of cancer in males based on the 1941 malignant
neoplasms recorded in Kingston and St. Andrew among
males. The authors reported 619 cases of prostate cancer
and age-standardized incidence rate of 56.4. In 2002,
Blake et al. [20] also reported that prostate cancer contin-
ued to be the leading cancer mortality site among Jamai-
can men.
The three published studies found to be relevant for Trini-
dad and Tobago were by Bunker et al. [21-23]. In 2004,
Bunker at al [21] reported a population-based prostate
cancer study, screening on about half the population of
Tobago men. Over 2,500 men between the age of 40 and
79 years were screened using serum prostate-specific anti-
gen (PSA) and digital rectal examination (DRE). The
authors found biopsy-confirmed prostate cancer preva-
lence in this population to be about 11% (277 out of
2,583 men). These results confirmed the findings of an
earlier report on the same population by Bunker et al. [22]
based on the screening of 2,484 men between the age of
40 and 79 in Tobago. In another report, Bunker et al. [23]
compared the Tobago population of West African descent
to the men of Asian-Indian descent in Trinidad, targeting
men between 50 and 64. The prostate cancer prevalence
based on population-based screening was found to be sig-
nificantly higher for the Afro-Tobagonian men (8.3%)
compared to the Asian-Indian men (2.3%). This differ-
ence was also observed on all age categories: 50–54; 55–
59; and 60–64.
Tracing the root of prostate cancer disparities to United 
Kingdom
The populations of Black men in the United Kingdom (UK)
provide a very interesting population to study because
they are mostly Afro-Caribbean and West African men.
Thereby, they uniquely reflect a microcosm of the West
African and Caribbean populations described above. Eth-
nic variations in prostate cancer have just recently been
studied in the UK, with the landmark study of The Prostate
Cancer in Ethnic Subgroups (PROCESS) group [24,25].
Chinegwundoh et al [24] published an earlier study in
2006. The researchers conducted a population-based
audit of new prostate cancer diagnosis between January 1,
1999 and December 31, 2000 for the following regions:
the London Boroughs of Tower Hamlets; Hackney; New-
ham; and the City of London. The total population in
these regions was over 600,000 with an ethnic classifica-
tion of White (British, Irish, "other" White), Black (Black
Caribbean, Black African, Other Black, White and Black
African mixed, White and Black Caribbean mixed), and
Asian (Indian, Pakistani, Bangladeshi, other Asian, White
& Asian mixed). The confirmed prostate cancer cases
included 248 European men, 91 African-Caribbean men,
and 20 South Asian men. These ethnic groups were com-
pared on age-adjusted incidence rates for prostate cancer.
The author's findings are summarized in Figures 1 and 2.
African-Caribbean men had the highest age-specific inci-
dence rates compared to European and Asian men. Inter-
estingly, the relative risk for prostate cancer for the
African-Caribbean men was three times that of European
Age-adjusted prostate cancer incidence rates comparing UK  European, African Caribbean, and South Asian men, age 50  and above, between 1999 and 2000 Figure 1
Age-adjusted prostate cancer incidence rates com-
paring UK European, African Caribbean, and South 
Asian men, age 50 and above, between 1999 and 
2000. *Incidence rate is per 100,000. Source: Chinegwundoh 
F, Enver M, Lee A, Nargund V, Oliver T, Ben-Shlomo Y. Risk 
and presenting features of prostate cancer amongst African-
Caribbean, South Asian and European men in North-east 
London. BJU International 2006, 98:1216–1220. [24]
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men. As noted by the authors, this risk is more than the
risk documented for African American men in the US. A
reason that has been suggested for the larger relative dif-
ference between African-Caribbean and European men is
a lower prostate cancer rate for White men in the UK [25].
In a follow-up study published this year, the PROCESS
study group [25] conducted a retrospective population-
based audit of prostate cancer incidences in North Bristol,
South West London, South East London, and North East
London from 1997 to 2001. Within this 5-year period, 2
140 prostate cancer cases were reported with: 61.4%
White, 20% Black Caribbean, 4.8% Black African, 0.5%
Black unclassified, 6% other ethnic groups, and 7% un-
coded ethnicity. A summary of the findings are provided
in Figures 3, 4, 5, 6. The authors confirmed their previous
findings in the Chinegwundoh et al.'s study [24]. An inter-
esting component of the current study is the comparison
of the Black Caribbean group to the Black African group,
with no statistically significant difference on age-adjusted
prostate cancer rates between both groups.
Discussion and conclusion
Based on the growing literature on the disproportionate
burden of prostate cancer among other Black men of West
African ancestry, it is clear that this clearly follows the path
of the TAS. The primary West African source populations
for the TAS were the African countries – Benin, Nigeria,
Ghana, Gambia and Senegal. Our critical review of the lit-
erature on these West African countries found that the true
prostate cancer rates reported for West Africans by the
WHO [11] may be underestimated. This is not surprising
since there are no data available on cancer incidence and
mortality for most of the West African countries. Contrary
to the global ranking, several published studies, including
our previous review article for Nigeria [8], indicate higher
incidence of prostate cancer in Nigeria [26-40] and Ghana
[13,14]. There are no published literature for Benin, Gam-
bia and Senegal. Prostate cancer morbidity and/or mortal-
ity data from the Caribbean Islands [10,15-23] and the
UK [24,25] also provide similar or worse prostate cancer
burden for Black men of West African ancestry.
Age-adjusted risk ratios for prostate cancer comparing UK  Black Caribbean and White men, age 40 and above, between  1997 and 2001 Figure 4
Age-adjusted risk ratios for prostate cancer compar-
ing UK Black Caribbean and White men, age 40 and 
above, between 1997 and 2001. *P value < 0.0001. 
Source: Ben-Shlomo Y, Evans S, Ibrahim F, Patel B, Anson K, 
Chinegwundoh F et al: The Risk of Prostate Cancer amongst 
Black Men in the United Kingdom: the Process Cohort Study. 
Eur Urol 2008, 53:99–105. [25]
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Age-adjusted prostate cancer incidence rates comparing UK  European, African Caribbean, and South Asian men, age 40  and above, between 1997 and 2001 Figure 3
Age-adjusted prostate cancer incidence rates com-
paring UK European, African Caribbean, and South 
Asian men, age 40 and above, between 1997 and 
2001. *Incidence rate is per 100,000. Source: Ben-Shlomo Y, 
Evans S, Ibrahim F, Patel B, Anson K, Chinegwundoh F et al: 
The Risk of Prostate Cancer amongst Black Men in the 
United Kingdom: the Process Cohort Study. Eur Urol 2008, 
53:99–105. [25]
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Age-adjusted risk ratios for prostate cancer comparing UK  European, African Caribbean, and South Asian men, age 50  and above, between 1999 and 2000 Figure 2
Age-adjusted risk ratios for prostate cancer compar-
ing UK European, African Caribbean, and South 
Asian men, age 50 and above, between 1999 and 
2000. *P value < 0.001 for European vs. African Caribbean. 
†P value = 0.13 for European vs. South Asian. Source: 
Chinegwundoh F, Enver M, Lee A, Nargund V, Oliver T, Ben-
Shlomo Y. Risk and presenting features of prostate cancer 
amongst African-Caribbean, South Asian and European men 
in North-east London. BJU International 2006, 98:1216–1220. 
[24]
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Table 1 provides a summary of the numerical findings of
published incidence and prevalence rates for prostate can-
cer in Black men of West African Ancestry. It is worth not-
ing that the direct comparisons of these numerical
findings may not be valid given the differences in the data
reporting methods for the incidence and prevalence of,
and mortality from prostate cancer in these countries. The
validity of the data reporting methods are further limited
in African countries due to underreporting [26], lack of
appropriate diagnosis [26,27,37,41], limited access to
care [41], differences in technical manpower and infra-
structure [41], and the quality of cancer data systems [41-
45].
The consistent higher incidence of prostate cancer relative
to other groups, observed in populations of West African
descent may be attributed to the fact that these popula-
tions share ancestral genetic factors that increase suscepti-
bility to prostate cancer. However, the likely variability in
risk across these populations of African men around the
world may also suggest a potential and important influ-
ence of environmental/lifestyle factors acting on prostate
cancer risk in these susceptible populations. To date the
disparate incidence of prostate cancer in African American
men in the US compared to their Caucasian counterparts
is poorly understood. Although modifiable exposures
related to lifestyle or environment is believed to play a
major role in the etiology of prostate cancer, the specific
causal factors remain elusive. To identify these causal fac-
tors and to better understand and address the global pros-
tate cancer disparities seen in Black men, it is important to
distinguish genetic and environmental determinants of
prostate cancer in men of West African ancestry, especially
the original TAS source population for African American
men. As delineated by Odedina, Ogunbiyi and Ukoli [8],
even with the available and emerging data, there are more
questions than answers at this time: Does the similar genetic
characteristic of Black men of West African ancestry put them
at higher risk for prostate cancer compared with other groups?
Are there common environmental conditions/lifestyle factors
among these men that may be responsible for the prostate can-
cer burden experienced by this group? What is the relative con-
tribution of genetic, lifestyle and environmental factors in
prostate cancer incidence and mortality among this group? Our
report establishes and provides a clear need, in addition to
delineating the next steps, for a systematic and compre-
hensive evaluation of these populations that can facilitate
a better understanding of the etiology of unequal burden
of this disease in African American men.
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Chinegwundoh F et al: The Risk of Prostate Cancer amongst 
Black Men in the United Kingdom: the Process Cohort Study. 
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above, between 1997 and 2001. *P value < 0.0001. 
Source: Ben-Shlomo Y, Evans S, Ibrahim F, Patel B, Anson K, 
Chinegwundoh F et al: The Risk of Prostate Cancer amongst 
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cles on the burden of prostate cancer in the Caribbean
ancestral groups of U.S. Black men. All the authors
reviewed and approved the manuscript.
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